Germany to Review Price of Eisai’s Fycompa

Epilepsy patients in Germany may gain access to Eisai’s drug, Fycompa, again after Germany’s Federal Joint Committee agreed to take another look at the drug’s pricing. Last year, Eisai announced that they would be withdrawing Fycompa (perampanel) from the German market as opposed to selling the epilepsy drug at the price approved by the Germany’s

Continue Reading

Eisai Suspends Epilepsy Drug, Fycompa, in Germany

Eisai is to suspend commercial distribution of its new epilepsy drug Fycompa in Germany, noting that they continue to disagree with the country’s reimbursement regulatory body’s rejection of the therapy. In March, the German Federal Joint Committee declared that they consider the additional benefit of Fycompa unproven when compared to two other treatments – GlaxoSmithKline’s

Continue Reading

Arena and Eisai Resubmit Lorcaserin to FDA

Arena Pharmaceuticals and partner Eisai are optimistic that regulators will approve their obesity drug, lorcaserin, after responding to a rejection issued by the US Food and Drug Administration in October 2010. Arena has submitted their response to the comprehensive reply letter from the Food and Drug Administration which cited a number of reasons for their

Continue Reading

Eisai’s Halaven Receives Final Draft “No” From NICE

In final draft guidance given yesterday, the National Institute for Health and Clinical Excellence (NICE) announced that they are not recommending Eisai’s Halaven (eribulin) for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Although the evidence shown to NICE’s independent

Continue Reading